Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
2,652.9
16.2 (0.62%)

 

  • STI Straits Times Index
    2,652.9
    16.2 (0.62%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,552.7
    16.4 (1.07%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    25,373.1
    248.9 (0.99%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    3,152.8
    62.2 (2.01%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    22,306.5
    160.5 (0.72%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    4,973.8
    7.0 (0.14%)
    Index delayed 10 minutes

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 1,532.5M
  • Value: 907.4M
  • Rise: 181
  • Fall: 116
  • Unch: 511

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Medtecs Intl0.500+0.035
IPS Securex0.105+0.015
LionGold0.002-
Oceanus^0.007-
Secura0.094+0.003
Synagie0.191+0.012
ThaiBev0.695+0.020
Singapore-eDev0.115-0.001
New Wave0.011-0.001
Asian Micro0.004-

World Indices

World Indices
Name Last Change
Nasdaq 9,757.2 -259.8
HSI 24,253.8 -296.2
HSCEI 9,745.8 -107.4
Jakarta 4,863.1 -41.0
Nikkei 225 22,064.8 -447.3
SSE Comp 2,959.0 -11.7
Shanghai A 3,101.5 -12.2
Shanghai B 211.6 -1.8
KOSPI 2,100.4 -34.3

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

Hyphens Pharma HYPHENS PHARMA INTL LIMITED
Quotes 10 Minutes Delayed. Updated at 03 Jul 2020 17:06
Last (SGD): 0.295 Change: - High: 0.300 Remarks: -
Change (%): - Low: 0.290
Open 0.300 Yesterday's Close 0.295
Buy Price 0.290 Sell Price 0.300
Buy Volume ('000) 316.7 Sell Volume ('000) 122.4
Cumulative Volume ('000) 778.5 Cumulative Value 229,265
Click to show Stock Prices chart

Key Statistics

EPS (SGD) a 0.02174 Trailing EPS (SGD) e 0.02405 NAV (SGD) b 0.1536
PE a 13.569 Trailing PE f 12.267 Price / NAV b 1.9206
Dividend (SGD) d 0.010000 Cash In Hand (SGD) g 0.0925 Issued & Paid-up Shares c 300,430,000
Dividend Yield (%) d 3.390 Price / Cash In Hand g 3.189 Treasury Shares h -
Beta - 75 Daysi 0.330 R-Squared - 75 Days(%)i 2.07 Market Cap (M) 88.627
Beta - 500 Daysi 0.377 R-Squared - 500 Days (%)i 2.20 Enterprise Value (M) 64.558
Piotroski F Score 6 Exchange Code 1J5 Par Value ( SGD ) n.a.
52 Weeks Volatility (%) 42.8512 6-Month VWAP 0.294 Free Float (%) 19.6
Under CPF Investment Scheme (CPFIS) No
Sector & Industry Wholesale and Retail Trade - Pharmaceuticals: Major
Category Classification Medical & Biotechnology
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 25 Jun 2020.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand.
  9. Beta and R-Squared are calculated in relation to the market index (STI or KLCI) using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference Hyphens Pharma SGX 88.627 13.569 12.267 1.9206 3.390
Industry Medical & Biotechnology SGX 989.499 20.509 22.500 1.3084 2.063
Pharmaceuticals: Major SGX 84.950 2006.700 134.132 3.4792 1.179
Local Peer IX Biopharma SGX 158.979 - - 10.5150 -
Local Peer Pharmesis Intl SGX 7.245 - - 0.6040 -
Global Peer JOHNSON & JOHNSON NYSE 371,398.152 24.565 21.636 6.0593 2.658
Global Peer NOVARTIS AG ADR-EACH REPR 1 CHF0.5(REGD) NYSE 216,040.444 30.652 21.647 - 2.104
Global Peer MERCK & CO INC NYSE 198,848.598 20.202 19.597 7.5882 2.886
Global Peer PFIZER INC NYSE 191,697.183 11.781 12.140 2.9488 4.215
Global Peer ABBVIE INC NYSE 174,260.179 22.221 20.768 -23.5009 3.726
Global Peer ELI LILLY AND COMPANY NYSE 156,829.817 33.815 28.343 50.9388 1.575
Global Peer ASTRAZENECA SPON ADR EACH REP 0.50 ORD SHS NYSE 141,200.252 105.331 189.853 - 2.546
Global Peer BRISTOL-MYERS SQUIBB CO NYSE 133,815.487 38.911 140.268 2.6811 2.797
Global Peer SANOFI SPON ADR ECH REP 0.5 ORD SHS NASDAQ 129,507.353 39.804 39.804 1.9577 2.272
Global Peer NOVO NORDISK A/S ADR-EACH CNV INTO 1 CLASS B DKK1 NYSE 120,281.482 20.599 20.018 15.0374 1.714
Other Global Peers GLAXOSMITHKLINE ADR EACH CNV INTO 2 ORD GBP0.25 (NYSE), TAKEDA PHARMACEUTICAL CO LTD SPON ADS EACH REP 0.5 ORD SHS (NYSE), WUXI APPTEC (HKEx), HANSOH PHARMA (HKEx), ROYALTY PHARMA PLC (NASDAQ), INNOVENT BIO (HKEx), SINOPHARM (HKEx), REPLIGEN CORP (NASDAQ), CANSINOBIO-B (HKEx), REATA PHARMACEUTICALS INC (NASDAQ), LEGEND BIOTECH CORP SPON ADS EACH REP 2 ORD SHS (NASDAQ), SH PHARMA (HKEx), GRIFOLS SA SPON ADR EA REPR 1 ORD EUR0.10 (NASDAQ), BAIYUNSHAN PH (HKEx), NEKTAR THERAPEUTICS (NASDAQ), BIOHAVEN PHARMACEUTICAL HLDG CO LTD (NYSE), HUTCHISON CHINA MEDITECH SPON ADS EACH REPR 5 ORD SHS (NASDAQ), CHINARES PHARMA (HKEx), AKESO-B (HKEx), HENLIUS-B (HKEx), ADC THERAPEUTICS SA (NYSE), ALLAKOS INC (NASDAQ), CMS (HKEx), KARUNA THERAPEUTICS INC (NASDAQ), TURNING POINT THERAPEUTICS INC (NASDAQ), APELLIS PHARMACEUTICALS INC (NASDAQ), TRAD CHI MED (HKEx), CHINAGRANDPHARM (HKEx), INNOCARE-B (HKEx), OPKO HEALTH INC (NASDAQ), IGM BIOSCIENCES INC (NASDAQ), SSY GROUP (HKEx), FORMA THERAPEUTICS HLDGS INC (NASDAQ), PRINCIPIA BIOPHARMA INC (NASDAQ), SPRINGWORKS THERAPEUTICS INC (NASDAQ), I MAB SPON ADS EACH REP 2.3 ORD SHS (NASDAQ), Y-MABS THERAPEUTICS INC (NASDAQ), ZYMEWORKS INC (NYSE), UNITED LAB (HKEx), AKCEA THERAPEUTICS INC (NASDAQ), CSTONE PHARMA-B (HKEx), KINIKSA PHARMACEUTICALS LTD (NASDAQ), ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS (NASDAQ), CONSTELLATION PHARMACEUTICALS INC (NASDAQ), JUNSHI BIO-B (HKEx), AMNEAL PHARMACEUTICALS INC (NYSE), TRICIDA INC (NASDAQ), ODONATE THERAPEUTICS INC (NASDAQ), ARCUTIS BIOTHERAPEUTICS INC (NASDAQ), TONGRENTANGCM (HKEx), CKLIFE SCIENCES (HKEx), ATHENEX INC (NASDAQ), REPARE THERAPEUTICS INC (NASDAQ), PHIBRO ANIMAL HEALTH CORP (NASDAQ), PETIQ INC (NASDAQ), GOSSAMER BIO INC (NASDAQ), HUA MEDICINE-B (HKEx), ARCTURUS THERAPEUTICS HOLDINGS INC (NASDAQ), AKERO THERAPEUTICS INC (NASDAQ), PHATHOM PHARMACEUTICALS INC (NASDAQ), GENERATION BIO CO (NASDAQ), ORIC PHARMACEUTICALS INC (NASDAQ), KRYSTAL BIOTECH INC (NASDAQ), G1 THERAPEUTICS IN (NASDAQ), PROVENTION BIO INC (NASDAQ), QUANTERIX CORPORATION (NASDAQ), APREA THERAPEUTICS INC (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), KEROS THERAPEUTICS INC (NASDAQ), OYSTER POINT PHARMA INC (NASDAQ), FUSION PHARMACEUTICALS INC (NASDAQ), NAVIDEA BIOPHARMACEUTICALS INC (NYSE American), RELMADA THERAPEUTICS INC (NASDAQ), KALA PHARMACEUTICALS INC (NASDAQ), ORCHARD THERAPEUTICS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), CRINETICS PHARMACEUTICALS INC (NASDAQ), IGBB (Bursa), CALLIDITAS THERAPEUTICS AB SPON ADS EACH REP 2 ORD SHS (NASDAQ), SHINEWAY PHARM (HKEx), MIRUM PHARMACEUTICALS INC (NASDAQ), AC IMMUNE SA (NASDAQ), OCULAR THERAPEUTIX INC (NASDAQ), IMARA INC (NASDAQ), FULCRUM THERAPEUTICS INC (NASDAQ), SIGA TECHNOLOGIES INC (NASDAQ), SATSUMA PHARMACEUTICALS INC (NASDAQ), BIOSPECIFICS TECHNOLOGIES CORP (NASDAQ), Kimia Farma Tbk. (IDX), BEYONDSPRING INC (NASDAQ), DURECT CORP (NASDAQ), AEGLEA BIOTHERAPEUTICS INC (NASDAQ), OVID THERAPEUTICS INC (NASDAQ), OSMOTICA PHARMACEUTICALS PLC (NASDAQ), 89BIO INC (NASDAQ), TCR2 THERAPEUTICS INC (NASDAQ), IDEAYA BIOSCIENCES INC (NASDAQ), TOT BIOPHARM-B (HKEx), FUSEN PHARM (HKEx), UROVANT SCIENCES LTD (NASDAQ), OBSEVA SA (NASDAQ), POLYPID LTD (NASDAQ), STARPHARMA HOLDINGS LIMITED (ASX), LIQUIDIA TECHNOLOGIES INC (NASDAQ), LANNETT CO INC (NYSE), MENLO THERAPEUTICS INC (NASDAQ), BSTEAD (Bursa), HOOKIPA PHARMA INC (NASDAQ), AMAG PHARMACEUTICS INC (NASDAQ), SPERO THERAPEUTICS INC (NASDAQ), KALEIDO BIOSCIENCES INC (NASDAQ), SUTRO BIOPHARMA INC (NASDAQ), VERRICA PHARMACEUTICALS INC (NASDAQ), AFT PHARMACEUTICALS LTD (ASX), GRITSTONE ONCOLOGY INC (NASDAQ), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), PYC THERAPEUTICS LIMITED (ASX), EVELO BIOSCIENCES INC (NASDAQ), KALVISTA PHARMACEUTICALS INC (NASDAQ), VERU INC (NASDAQ), CH BIOTECH SER (HKEx), GAMIDA CELL LTD (NASDAQ), NEUBASE THERAPEUTICS INC (NASDAQ), SOL GEL TECHNOLOGIES LTD (NASDAQ), LOGICBIO THERAPEUTICS INC (NASDAQ), SCPHARMACEUTICALS INC (NASDAQ), EVOLUS INC (NASDAQ), IMMUNIC INC (NASDAQ), DAWNRAYS PHARMA (HKEx), GALERA THERAPEUTICS INC (NASDAQ), AVENUE THERAPEUTICS INC (NASDAQ), MUSTANG BIO INC (NASDAQ), PROTARA THERAPEUTICS INC (NASDAQ), CYCLERION THERAPEUTICS INC (NASDAQ), BIONDVAX PHARMACEUTICALS SPON ADS REP 40 ORD SHS (NASDAQ), TYME TECHNOLOGIES INC (NASDAQ), AQUESTIVE THERAPEUTICS INC (NASDAQ), THERATECHNOLOGIES INC (NASDAQ), LYRA THERAPEUTICS INC (NASDAQ), PHARMA (Bursa), BIOMX INC (NYSE American), TREVI THERAPEUTICS INC (NASDAQ), HARROW HEALTH INC (NASDAQ), ESSA PHARMA INC (NASDAQ), PHASEBIO PHARMACEUTICALS INC (NASDAQ), XERIS PHARMACEUTICALS INC (NASDAQ), AYALA PHARMACEUTICALS INC (NASDAQ), ZHONGZHIPHARM (HKEx), GENPREX INC (NASDAQ), APTORUM GROUP LIMITED (NASDAQ), TFF PHARMACEUTICALS INC (NASDAQ), ETON PHARMACEUTICALS INC (NASDAQ), KITOV PHARMA LTD SPON ADS EACH REP 1 ORD SHS (NASDAQ), CHECKPOINT THERAPEUTICS INC (NASDAQ), KOTRA (Bursa), NC HEALTHCARE (HKEx), PAK FAH YEOW (HKEx), NEW RAY MEDIC (HKEx), MEDIWOUND LTD (NASDAQ), MILESTONE PHARMACEUTICALS INC (NASDAQ), EYEPOINT PHARMACEUTICALS INC (NASDAQ), Merck Tbk. (IDX), CLEARSIDE BIOMEDICAL INC (NASDAQ), ASSERTIO HOLDINGS INC (NASDAQ), CHARMACY PHAR (HKEx), LANTERN PHARMA INC (NASDAQ), Phapros Tbk. (IDX), RECCE PHARMACEUTICALS LTD (ASX), IP (SET), CORVUS PHARMACEUTICALS INC (NASDAQ), BAUDAX BIO INC (NASDAQ), PALLA PHARMA LTD (ASX), AKARI THERAPEUTICS PLC SPON ADR EACH REPR 100 ORD (NASDAQ), ONCOSIL MEDICAL LIMITED (ASX), RACE ONCOLOGY LTD (ASX), ARIDIS PHARMACEUTICAL INC (NASDAQ), EYENOVIA INC (NASDAQ), MOLECULIN BIOTECH INC (NASDAQ), CITIUS PHARMACEUTICALS INC (NASDAQ), ADDEX THERAPEUTICS LIMITED SPON ADS EACH REP 6 ORD SHS (NASDAQ), AERPIO PHARMACEUTICALS INC (NASDAQ), NEP INTERLONG (HKEx), NOVA (Bursa), ALLENA PHARMACEUTICALS INC (NASDAQ), ONCTERNAL THERAPEUTICS INC (NASDAQ), WAI YUEN TONG (HKEx), AILERON THERAPEUTICS INC (NASDAQ), EDESA BIOTECH INC (NASDAQ), HISTOGEN INC (NASDAQ), MANNATECH INC (NASDAQ), TBG DIAGNOSTICS LTD (ASX), ADAMIS PHARMACEUTICALS CORPORATION (NASDAQ), NOVAN INC (NASDAQ), PURAPHARM (HKEx), SANAI HEALTH GP (HKEx), JCT (SET), CNS PHARMACEUTICALS INC (NASDAQ), HOTH THERAPEUTICS INC (NASDAQ), AGEX THERAPEUTICS INC (NYSE American), IMMURON LIMITED (ASX), ACER THERAPEUTICS INC (NASDAQ), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), MILLENDO THERAPEUTICS INC (NASDAQ), ENTERA BIO LTD (NASDAQ), EXTRAWELL PHAR (HKEx), INVION LTD (ASX), ANNOVIS BIO INC (NYSE American), TITAN PHARMACEUTICAL INC (NASDAQ), NOXOPHARM LTD (ASX), MEDLAB CLINICAL LIMITED (ASX), BIOHLDG (Bursa), DARE BIOSCIENCE INC (NASDAQ), TIMBER PHARMACEUTICALS INC (NYSE American), PDS BIOTECHNOLOGY CORPORATION (NASDAQ), SPRING BANK PHARMACEUTICALS INC (NASDAQ), BRICKELL BIOTECH INC (NASDAQ), PHARMAXIS (ASX), SINOLIFE UTD (HKEx), ADIAL PHARMACEUTICALS INC (NASDAQ), ACRUX (ASX), EXOPHARM LTD (ASX), PROPHASE LABS INC (NASDAQ), CHINA SXT PHARMACEUTICALS INC (NASDAQ), PASHUN INT'L (HKEx), TALI DIGITAL LIMITED (ASX), TELIGENT INC NEW (NASDAQ), SUNZEN (Bursa), CRESO PHARMA LTD (ASX), CELLMID LIMITED (ASX), Merck Sharp Dohme Pharma Tbk. (IDX), NOVUS THERAPEUTICS INC (NASDAQ), FARMAFORCE LTD (ASX), FIJI KAVA LTD (ASX), SUDA PHARMACEUTICALS LTD (ASX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days --0.015
-4.84 %
10 Days --0.005
-1.67 %
20 Days --0.035
-10.61 %
Medium Term Return 3 Months 0.010+0.110
+64.86 %
6 Months 0.010+0.075
+38.64 %
1 Year 0.010+0.090
+48.78 %
Long Term Return 2 Years 0.016+0.080
+44.65 %
Annualised Return Annualised --
+20.27 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 0.180 - 0.390 Change From 1 Year Low +0.115 % Change From 1 Year Low (%) +63.89
Change From 1 Year High -0.095 % Change From 1 Year High (%) -24.36
2 Years Range 0.160 - 0.390 Change From 2 Years Low +0.135 % Change From 2 Years Low (%) +84.38
Change From 2 Years High -0.095 % Change From 2 Years High (%) -24.36
5 Years Range 0.160 - 0.390 Change From 5 Years Low +0.135 % Change From 5 Years Low (%) +84.38
Change From 5 Years High -0.095 % Change From 5 Years High (%) -24.36
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

Hyphens Pharma International Limited and its subsidiaries (the "Group") is one of Singapores leading specialty pharmaceutical and consumer healthcare groups leveraging on its diverse footprint in ASEAN countries. The Group has a direct presence in five ASEAN countries, namely, Singapore, Vietnam, Malaysia, Indonesia and the Philippines, supplemented by a marketing and distribution network covering five additional jurisdictions, namely, Hong Kong, Myanmar, Brunei, Cambodia and Oman. Singapore is the Groups regional headquarters, where its strategic planning, finance, regulatory affairs, research and development, legal, business development and logistics operations are based.The Groups core business comprises the following segments: specialty pharma principals, proprietary brands, and medical hypermart and digital. Besides marketing and selling a range of specialty pharmaceutical products in selected ASEAN countries through exclusive distributorship or licensing and supply agreements with brand principals mainly from Europe and the United States, the Group also develops, markets and sells its own proprietary range of dermatological products and health supplement products. In addition, the Group operates a medical hypermart for healthcare professionals, healthcare institutions and retail pharmacies, to supply pharmaceutical products and medical supplies.

IPO Performance

Listing Date 18 May 2018 Full Subscription Rate (x) 17.91
No of Placement Shares (M) 23.79 No of Public Offer Shares (M) 3.00 Public Offer Subscription Rate (x) 151.99
IPO Price (SGD) a 0.260 First Day Close (SGD) a 0.275 First Week Close (SGD) a 0.260
Current vs IPO Price (%) +13.46 First Day Gain (%) +5.77 First Week Gain (%) -
Notes:
  1. Adjusted for the following: 23,790,000 Placement Shares do not include the 2,810,000 Reserved Shares.

Reports Download

Report Type Financial Year Ended Download
Annual Report
Annual Report 2019 Dec 2019 Part 1(6.40 MB)
Annual Report 2018 Dec 2018 Part 1(7.14 MB)
IPO Prospectus
IPO Prospectus 2018 May 2018 Part 1(2.57 MB)
Part 2(0.27 MB)

Historical Price Data

Date Open High Low Close Volume VWAP
03 Jul 2020 0.300 0.300 0.290 0.295 778,500 0.2945
02 Jul 2020 0.295 0.300 0.290 0.295 629,600 0.2953
01 Jul 2020 0.295 0.300 0.295 0.295 708,600 0.2976
30 Jun 2020 0.300 0.305 0.290 0.295 1,657,100 0.2982
29 Jun 2020 0.300 0.305 0.290 0.295 2,331,200 0.2957
26 Jun 2020 0.320 0.320 0.305 0.310 724,500 0.3085
25 Jun 2020 0.310 0.315 0.305 0.315 1,036,600 0.3124
24 Jun 2020 0.325 0.330 0.310 0.315 3,335,400 0.3213
23 Jun 2020 0.300 0.335 0.290 0.330 8,249,000 0.3203
22 Jun 2020 0.305 0.305 0.295 0.300 710,600 0.2967
19 Jun 2020 0.305 0.310 0.300 0.300 1,413,100 0.3065
18 Jun 2020 0.300 0.310 0.290 0.300 2,036,000 0.3047
17 Jun 2020 0.305 0.305 0.295 0.295 713,900 0.2996
16 Jun 2020 0.310 0.310 0.300 0.300 1,545,700 0.3035
15 Jun 2020 0.310 0.315 0.290 0.300 975,400 0.3017
12 Jun 2020 0.290 0.310 0.290 0.305 1,819,300 0.3008
11 Jun 2020 0.320 0.330 0.300 0.300 3,160,900 0.3115
10 Jun 2020 0.305 0.330 0.300 0.320 4,706,400 0.3163
09 Jun 2020 0.330 0.330 0.300 0.300 3,390,800 0.3111
08 Jun 2020 0.335 0.340 0.320 0.325 6,067,100 0.3317
05 Jun 2020 0.315 0.335 0.315 0.330 3,717,300 0.3297
04 Jun 2020 0.325 0.330 0.305 0.315 3,834,100 0.3170
Summary
Current 2 Weeks
(22 Jun 2020 to 03 Jul 2020)
0.305 0.335 0.290 0.295 20,161,100 -
Previous 2 Weeks
(08 Jun 2020 to 19 Jun 2020)
0.335 0.340 0.290 0.300 25,828,600 -
4 Weeks from
(08 May 2020 to 05 Jun 2020)
0.250 0.335 0.245 0.330 124,905,400 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.
We use Cookies. By continuing to use this webite, you will be agreeing to our Privacy Policy, Terms and Conditions and Cookie Policy.